IVI Provides Insight into CVS Health’s Decision to Include Cost-per-QALY Analyses from ICER into Formulary Decision-Making
CVS Health’s pharmacy benefit management (PBM) division, CVS Caremark, recently announced their decision to rely exclusively on the analyses of the Institute for Clinical and Economic (ICER) in a new drug management program. IVI’s Director of Scientific Communications, Mark Linthicum, responds to this story in MedCity stating, “The neat ‘answer’ regarding the value of treatment […]
Why Quality Measures Must Reflect Patient Values, Care Experience
There isn’t an easy answer to assessing value in healthcare, but IVI is working to tackle the problems through considerable research and experimentation by developing an open-source value platform that considers no only clinical factors, but patient perspectives as well. In a recent interview with PatientEngagementHIT.com, IVI’s Jennifer Bright (Executive Director) and Mark Linthicum (Director […]
How to Improve Value Assessment
In an op-ed published in Healthcare Business News, IVI’s Executive Director, Jennifer Bright, describes four essential steps necessary to better measure value in healthcare: Better value measurement must incorporate the patient perspective into all assessment tools. Real world data must be considered when determining a treatment’s worth beyond direct clinical benefit. Value assessments must be […]
Current Problems with Value Assessments and Ideas for Improvement
In an op-ed published by Fierce Healthcare, Director of Scientific Communications, Mark Linthicum discusses current shortfalls of value assessment and what is needed to move to value assessment 2.0. Read the full article here.
Patient-Centered Formularies: Steps in the Right Direction, but Challenges Remain
In a post on the IVI-sponsored Health Affairs featured blog series, Drugs and Medical Innovation, Jason Shafrin (IVI Director of Research) and Mark Linthicum (IVI Director of Scientific Communications) explore the role that formularies play in determining value for different stakeholders, and how unique, multi-stakeholder efforts can make formularies more patient-centered. Read the full article […]
Using Outcomes-Based Pricing for Medical Devices to Improve Cardiovascular Disease Treatment Value
In a post on the IVI-sponsored Health Affairs featured blog series Drugs and Medical Innovation, Daniel Blumenthal, Samuel Nussbaum (IVI Strategic Advisory Panel Chair), Mark Linthicum (IVI Director of Scientific Communications), and Neil Weissman (IVI Strategic Advisory Panel member) explore how outcomes-based pricing agreements (OBAs) could be utilized for medical devices used to treat cardiovascular […]
Putting More Value Into Biopharmaceutical Value Assessments
In a commentary for the Health Affairs Blog, Rena M. Conti, PhD, and IVI Executive Director, Darius Lakdawalla, argue that advancing the science of value assessment requires new assessment tools that are transparent and incorporate the perspectives of patients and insurance plan enrollees. Read the full article here.
To Get Our Money’s Worth in Healthcare, We Need to Collaborate
In a commentary for Modern Healthcare, IVI Director of Scientific Communications, Mark Linthicum, emphasizes that the healthcare system needs to embrace collaboration to find consensus in the way we measure and pay for health care value. Read the full article here.
Well-Informed Patients Play a Key Role in Value-Based Care
In a commentary for Morning Consult, Virginia Ladd, President and Executive Director of the American Autoimmune Related Diseases Association (AARDA), emphasizes how critical it is that the patient perspective be front and center in discussions about how we measure and pay for value. Read the full article here.
An Open-Source Consensus-Based Approach to Value Assessment
In a commentary for the Health Affairs Blog, IVI’s Jeroen Jansen, Devin Incerti, and Mark Linthicum argue that, in order to move toward consensus on value assessment, the process for defining and measuring value must be transparent, collaborative, and iterative. IVI is taking the first steps towards consensus with the development of the Open-Source Value Project. […]